Hyperfine (NASDAQ:HYPR) vs. ClearPoint Neuro (NASDAQ:CLPT) Financial Comparison

Hyperfine (NASDAQ:HYPR) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Hyperfine and ClearPoint Neuro, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1	2	3	0	2.33
ClearPoint Neuro	1	0	2	0	2.33

Hyperfine currently has a consensus target price of $1.59, indicating a potential downside of 7.16%. ClearPoint Neuro has a consensus target price of $14.50, indicating a potential upside of 30.63%. Given ClearPoint Neuro’s higher probable upside, analysts plainly believe ClearPoint Neuro is more favorable than Hyperfine.

Earnings and Valuation

This table compares Hyperfine and ClearPoint Neuro”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40 million	14.69	-$35.57 million	($0.44)	-3.89
ClearPoint Neuro	$36.97 million	9.00	-$25.54 million	($0.91)	-12.20

ClearPoint Neuro has higher revenue and earnings than Hyperfine. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Hyperfine has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.

Insider and Institutional Ownership

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 26.3% of Hyperfine shares are held by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Hyperfine and ClearPoint Neuro’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperfine	-262.29%	-95.09%	-71.11%
ClearPoint Neuro	-69.08%	-122.17%	-40.69%

Summary

Hyperfine beats ClearPoint Neuro on 7 of the 13 factors compared between the two stocks.

About Hyperfine

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.

About ClearPoint Neuro

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.